Galatasaray Eye Donnarumma After Ederson Talks Stall
Galatasaray Eye Donnarumma After Ederson Talks Stall
Galatasaray've turned their sights to Italy's Gianluigi Donnarumma with negotiations for Man City's Ederson proving difficult according to Spanish outlet AS.
Ter Stegen Blow Ends Initial Plan
The Turkish champions initially targeted Marc Andre ter Stegen hoping to lure him after he reportedly fell out of favor under new Barcelona coach Hansi Flick.
However a back injury has ruled out the German goalkeeper forcing Galatasaray to halt discussions.
Ederson Deal Hits Financial Roadblock
Galatasaray reached personal agreement with Ederson offering the Brazilian shot stopper net salary of 6 million euro per year plus bonuses. But Man City are demanding 10 million euro for the transfer, a fee the Turkish side's hesitant to match.
Donnarumma Now on the Radar
With Ederson's move stalling Gianluigi Donnarumma's emerged as viable Plan B. The PSG goalkeeper's future remains uncertain as his contract expires next summer and no renewal has been agreed.
Galatasaray's head of transfers Abdullah Kavukcu confirmed to AS:
"We have list of targets. Donnarumma's among them but we must evaluate the financial conditions carefully"
Meanwhile head coach Okan Buruk added:
"Donnarumma's exceptional keepe of course I'd want him. Ederson's also great option but nothing is finalized"
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Barcelona release statement following Marc-Andre ter Stegen surgery
Barcelona have confirmed that captain Marc-Andre ter Stegen has undergone surgery for a recurring back problem. There is plenty of intrigue surrounding his diagnosis, given the length of his injury could have a major impact on Barcelona's ability to register new players in the coming month. The German goalkeeper announced the decision last week, explaining that he would be out for three months, one month short of the required four-month period for Barcelona to activate La Liga's injury rule. That would allow them to use 80% of the amount of ter Stegen's salary limit cost towards other players on a temporary basis, with new additions Roony Bardghji, Marcus Rashford and Joan Garcia currently unregistered. Marc-Andre ter Stegen of FC Barcelona warms up during the Spanish league, La Liga EA Sports, football match played between Villarreal CF and FC Barcelona at La Ceramica stadium on September 22, 2024, in Valencia, Spain. AFP7 22/09/2024 ONLY FOR USE IN SPAIN No timeline given on recovery for ter Stegen It means their ability to do so may hinge on the medical report written up by surgeon Amelie Leglise, who operated on ter Stegen on Tuesday. That much was confirmed by Barcelona, but they did not give a recovery period. Barcelona to submit medical report to La Liga It had been suggested last week by another doctor that ter Stegen's announcement will have little impact on La Liga's ruling. The Blaugrana now have 30 days to submit a report to La Liga, as per MD. Four members of the medical commission for La Liga will then give the green light to the league on the report they receive, provided they perceive no issues. Barcelona were reportedly very unhappy with ter Stegen's announcement, seeing it as deliberate sabotage of their plans, and questions have been raised over his captaincy for next season.
Yahoo
4 hours ago
- Yahoo
Barcelona issue official update on captain's surgery
Barcelona have officially confirmed that Marc-Andre ter Stegen has undergone a second surgery to address his ongoing lower back issues. The operation was carried out on Tuesday in Bordeaux by renowned specialist Dr Amelie Leglise, with the club's medical team closely involved. While the procedure was deemed a success, Barça have, as expected, avoided offering a clear timeline for his return to action. In the club's official statement, they said: 'First-team player Marc ter Stegen has successfully undergone further surgery for his lower back problems, performed by Dr. Amelie Leglise under the supervision of the club's Medical Services at Sports Clinic Bordeaux Merignac. 'He is unavailable for selection, and his recovery will determine when he can return.' While no fixed recovery time has been shared by the club, the fact that they have stayed silent suggests the situation may be more serious than initially hoped. Facing uncertain future The German international had returned from his summer break feeling discomfort in his lower back and was unable to join his teammates for pre-season training. He also missed the club's Asian tour, instead focusing entirely on medical treatment. Ter Stegen had earlier taken to social media to reveal that he expected to be sidelined for around three months. However, La Liga rules state that a player must be unavailable for a minimum of four months before the club can repurpose 80% of their salary for new signings. Barça's decision not to mention any recovery timeline might indicate that his absence will exceed even his own estimation. The 2025/26 season poses significant challenges for Ter Stegen. The arrival of Joan Garcia means there will be stiff competition for the number one shirt. Moreover, with the 2026 World Cup on the horizon, Ter Stegen is fully aware that missing significant game time now could hurt his chances of making Germany's squad.
Yahoo
5 hours ago
- Yahoo
Maziar Mike Doustdar appointed as president and chief executive officer of Novo Nordisk
Bagsværd, Denmark, 29 July 2025 – Novo Nordisk today announced that Maziar Mike Doustdar has been appointed as president and chief executive officer, effective 7 August 2025. Mike Doustdar succeeds Lars Fruergaard Jørgensen, who will step down as president and chief executive officer on the same date. The company also announced other executive-level changes, effective 7 August. Mike Doustdar, currently Novo Nordisk's executive vice president of International Operations, has a strong track record of creating value and driving growth. Under his leadership over the past decade, Novo Nordisk's International Operations have more than doubled sales to approximately DKK 112 billion in 2024. The business includes all of Novo Nordisk's affiliates outside of the US and employs nearly 20,000 people. Novo Nordisk Chair, Helge Lund, said: 'Mike is an exceptional leader and has the unanimous support of the Board. We are confident that he is the best person to lead Novo Nordisk through its next growth phase. Mike has consistently demonstrated the ability to drive growth through strong commercial execution and building high-performing teams. This is an important moment for Novo Nordisk. The market is developing rapidly, and the company needs to address recent market challenges with speed and ambition. I believe Novo Nordisk will build on its strengths as a global leader in obesity and diabetes, and Mike has a clear vision of how to unlock the full potential of the opportunities ahead.' Mike Doustdar has been appointed as the result of a comprehensive process that included external and internal candidates. The Novo Nordisk Foundation fully endorses Novo Nordisk Board's decision to appoint Maziar Mike Doustdar as president and chief executive officer. Mike Doustdar said: 'It's an enormous privilege to lead this company at a time of tremendous opportunity and change. I come to this role with a sense of urgency, a laser focus on high performance, and a fierce determination for Novo Nordisk to aim higher than it's ever done, and to deliver to many more patients the innovation they need. From my decades in leadership roles across Novo Nordisk, I know the extraordinary talent and commitment of our people and the excellence of our science. This has enabled us to achieve great things in the past and will ensure we continue to do so in the future.' Novo Nordisk Chair, Helge Lund, added: 'Under Lars's leadership, Novo Nordisk has undergone a profound period of growth and now reaches millions more patients with life-changing medicines. On behalf of Novo Nordisk's Board of Directors and our employees, I want to thank Lars for 34 years of unstinting commitment to the company and wish him all the best in his future endeavours.' Other organisational changes effective 7 August: Research & Early Development and Development EVP areas will be merged into a combined R&D Nordisk has decided to merge the company's Research & Early Development with its Development area into a new, consolidated R&D unit, under the leadership of Martin Holst Lange, MD, PhD. Martin Holst Lange, currently executive vice president, Development, will be appointed chief scientific officer (CSO), effective 7 August. Martin Holst Lange will focus on seamlessly combining the two functions, quickly advancing the innovation of new therapies and ensuring the success of the early and late-stage pipelines, with a significant focus on the diabetes and obesity areas. In addition, Martin Holst Lange will work closely with Mike Doustdar to drive pipeline development and innovation from both within and outside of the company. Marcus Schindler, executive vice president, Research & Early Development and CSO, has decided to retire from the company. Novo Nordisk Chair, Helge Lund, said: 'We thank Marcus for his deep commitment to Novo Nordisk and its pursuit of scientific excellence. We wish him all the best for the future.' Marcus Schindler joined Novo Nordisk in January 2018 as senior vice president of External Innovation and Strategy and has been CSO since 2021. Marcus Schindler has played an integral role in leading the discovery of early scientific innovation. He will remain at Novo Nordisk for a short period to ensure a successful transition. Emil Kongshøj Larsen, currently senior vice president of the Europe and Canada region (EUCAN), will join Executive Management and succeed Mike Doustdar, assuming the responsibility of executive vice president, International Operations. Emil Larsen currently leads a region spanning 40 countries, accounting for about 20% of Novo Nordisk's global sales. He has previously led other significant business areas throughout Europe, Africa and the Middle East, as well as Commercial Affairs and Strategy in International Operations. With these changes, Executive Management will have the following members, effective 7 August: Maziar Mike Doustdar, president and CEO* Thilde Hummel Bøgebjerg, EVP, Quality, IT & Environmental Affairs Emil Kongshøj Larsen, EVP, International Operations Ludovic Helfgott, EVP, Product & Portfolio Strategy Karsten Munk Knudsen, EVP, chief financial officer* Martin Holst Lange, EVP, chief scientific officer, Research & Development David Moore, EVP, US Operations Tania Sabroe, EVP, People, Organisation and Corporate Affairs Henrik Wulff, EVP, CMC & Product Supply * Registered as an executive with the Danish Business Authority. About Maziar Mike DoustdarMike Doustdar became senior vice president of International Operations in 2013, a business that includes 80 affiliates - all of Novo Nordisk's commercial affiliates outside of the US. Novo Nordisk's International Operations had sales of approximately DKK 112 billion in 2024 and serve approximately 35 million patients. Prior to this role, Mike led Novo Nordisk's Southeast Asia and Oceania commercial area out of Malaysia, following on from his leadership of the Middle East business. Prior to this, he was general manager based in Turkey and held leadership roles in finance and IT. Mike Doustdar became executive vice president in 2015. He is a member of the Board of Directors of Orion Corporation. Conference CallNovo Nordisk will host a conference call for investors at 14.30 CEST on 29 July 2025, corresponding to 8.30 am EST. For more information on how to listen, please visit the investor section of There will be a conference call for media at 16.00 CEST, which corresponds to 10.00 am EST. Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 77,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit Facebook, Instagram, X, LinkedIn and YouTube. Contacts for further information Media: Ambre James-Brown +45 3079 9289abmo@ Liz Skrbkova (US)+1 609 917 0632lzsk@ Investors: Jacob Martin Wiborg Rode+45 3075 5956jrde@ Sina Meyer +45 3079 6656azey@ Max Ung+45 3077 6414 mxun@ Frederik Taylor Pitter +1 609 613 0568fptr@ Publication of inside information pursuant to Market Abuse Regulation, Article 17 Company announcement No 19 / 2025 Attachment CA250729-CEO-succession
